Using serial [68Ga]Ga-PSMA-11 PET scans, Emmett et al. [24] reported a 30% reduction in SUVmax after nine days of treatment with luteinizing hormone-releasing hormone (either with or without bicalutamide) in eight men with metastatic hormone-sensitive PC. The gene discussed is FOLH1; the disease is pachyonychia congenita.